SynKIR-210 / Verismo Therap - LARVOL DELTA

HLB Innovation Acquires US CAR-T Developer Verismo as 100% Subsidiary [Google translation] (HIT News) - "HLB Innovation has begun the process of incorporating Verismo Therapeutics, a U.S. CAR-T treatment developer, as a wholly owned subsidiary...HLB Innovation announced on the 5th through a public disclosure on the 4th that its 100% US subsidiary HLBI USA will be conducting a triangular stock exchange and merger with Verismo. The transaction method is that HLB Innovation will participate in HLBI USA’s paid-in capital increase, and HLBI USA will then participate in HLB Innovation’s paid-in capital increase, and the common stocks of HLB Innovation acquired through this will be distributed to Verismo’s existing shareholders....After HLBI USA and Verismo complete the merger process, HLB Innovation will acquire a 100% stake in Verismo."

M&A • Cholangiocarcinoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastrointestinal Cancer • Gynecologic Cancers • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Mesothelioma • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Solid Tumor